 |
|
|
| |
GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Rohit Loomba1, Eric Lawitz2, Parvez S. Mantry3, Saumya Jayakumar4, Stephen H. Caldwell5, Hays Arnold6, Anna Mae Diehl7, C. Stephen Djedjos8, Catherine Jia8, Robert P. Myers8, G. Mani Subramanian8,
John G. McHutchison8, Zachary D. Goodman9, Nezam H. Afdhal10, Michael R. Charlton11
1University of California at San Diego, San Diego, CA; 2Texas Liver Institute, San Antonio, TX;
3The Liver Institute at Methodist Dallas, Dallas, TX; 4University of Calgary, Calgary, AB, Canada;
5University of Virginia, Charlottesville, VA; 6Gastroenterology Consultants of San Antonio, San Antonio, TX;
7Duke Clinical Research Institute, Durham, NC; 8Gilead Sciences, Inc., Foster City, CA; 9Inova Fairfax Hospital, Falls Church, VA; 10Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;
11Intermountain Medical Center, Salt Lake City, UT
|
| |
|
|
|
|
|
